OKUR

OnKure Therapeutics

• NASDAQ·5d ago

  Biotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts

• TipRanks·05/07 05:57

  OnKure Therapeutics downgraded to Hold from Buy at JonesResearch

• TipRanks·05/06 12:41

  Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)

• TipRanks·05/06 12:31

  Analysts Offer Insights on Healthcare Companies: Revvity (RVTY), Option Care Health (OPCH) and OnKure Therapeutics (OKUR)

• TipRanks·05/06 12:00

  OnKure Therapeutics (OKUR) Receives a Buy from Oppenheimer

• TipRanks·05/06 11:16

  OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target

• Seeking Alpha·05/05 21:42

  OnKure Therapeutics GAAP EPS of -$1.11 misses by $0.37

• Dow Jones·05/05 20:41

  *OnKure Therapeutics 1Q Loss $15.2M >OKUR

• PUBT·05/05 20:09

  OnKure net loss narrows to $15.2 million in Q1 2026

• TipRanks·04/24 20:12

  OnKure Therapeutics files to sell 36.14M shares of Class A common for holders

• PUBT·04/21 20:19

  OnKure Therapeutics announces annual shareholder meeting notice

• Reuters·04/08 01:15

  OnKure Therapeutics initial beneficial ownership filing names AI Biotechnology LLC as 10% owner

• TipRanks·04/06 20:38

  OnKure Therapeutics (OKUR) Gets a Buy from JonesTrading

• Reuters·04/01 21:24

  OnKure Therapeutics files Form 3; director Liam Ratcliffe reports no beneficial ownership

• Reuters·03/30 11:16

  ONKURE THERAPEUTICS INC <OKUR.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $11 FROM $29